Sugi Predict

Sugi Predict / Compounds / SCHEMBL370184

SCHEMBL370184

SCHEMBL370184

COC(C)c1[nH]ncc1-c1csc(Nc2nccc(C)n2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 4/20 0.46
▸ CDK1 P06493 7/20 0.43
▸ CCNA2 P20248 7/20 0.43
▸ CDK2 P24941 7/20 0.43
▸ CCNB1 P14635 6/20 0.43
▸ CCNA1 P78396 6/20 0.43
▸ CDK4 P11802 6/20 0.43
▸ CCND1 P24385 5/20 0.43
▸ MEN1 O00255 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ ATM Q13315 1/20 0.42
▸ GRM8 O00222 1/20 0.41
▸ NPC1 O15118 6/20 0.39
▸ RAB9A P51151 6/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ PKM P14618 1/20 0.39
▸ TRPV4 Q9HBA0 2/20 0.38
▸ CCNE1 P24864 2/20 0.38
▸ CCND3 P30281 2/20 0.38
▸ CDK6 Q00534 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2536225 0.80 GRM4 (0.48) GRM4CDK1CCNA2CDK2CCNB1
SCHEMBL370530 0.78 GRM4 (0.47) GRM4MEN1KMT2AATMGRM8
SCHEMBL370620 0.77 GRM4 (0.46) GRM4CDK1CCNA2CDK2CCNB1
SCHEMBL2529837 0.76 NPC1 (0.47) GRM4CDK4CCND1MEN1KMT2A
SCHEMBL369500 0.76 GRM4 (0.46) GRM4MEN1KMT2AATMGRM8
SCHEMBL367343 0.74 GRM4 (0.64) GRM4MEN1KMT2AATMGRM8
SCHEMBL369774 0.74 GRM4 (0.46) GRM4CDK1CCNA2CDK2CCNB1
SCHEMBL369767 0.74 GRM4 (0.46) GRM4CDK1CCNA2CDK2CCNB1
SCHEMBL2534001 0.74 MEN1 (0.42) GRM4MEN1KMT2AATMGRM8
SCHEMBL370601 0.72 MEN1 (0.43) GRM4MEN1KMT2AATMGRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS BOLEA CHRISTELLE (CH) 2013-08-15 — — US claimed
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS BOLEA CHRISTELLE (CH) 2013-08-15 — — US disclosed
EP-2595986-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2013-05-29 — — EP disclosed
WO-2012009009-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM2, GRM4, GRM1 GRM4 2/4885CDK1 2418/4885CCNA2 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.